NasdaqGM:AUPHBiotechs
Aurinia Resets Leadership And Capital Plans As Valuation Gap Persists
Aurinia Pharmaceuticals has appointed Kevin Tang as CEO, alongside a new COO, CFO, and CSO, in a broad leadership reshuffle.
The board has been reduced in size, with several previous executives and directors departing.
The company is discontinuing non core R&D programs, introducing performance based incentives, and authorizing a substantial share repurchase plan.
Aurinia Pharmaceuticals (NasdaqGM:AUPH) is drawing attention as this leadership overhaul lands on a stock that closed at $14.21,...